Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Mineralys Therapeutics, Inc. (MLYS)
NASDAQ:MLYS
RESEARCH TOOLSreports
Earnings Data
Report Date
May 19, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-1.08Last Year’s EPS
-0.7Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 12, 2025
|% Change Since: -1.35%
|Next Earnings Date:May 19, 2025
Earnings Call Sentiment|Positive
The earnings call conveyed a positive outlook overall with strong clinical progress and a solid financial position, despite increased R&D expenses and net loss. The company remains optimistic about upcoming data readouts and market potential for lorundrostat.Company Guidance
During the Mineralys Fourth Quarter and Full Year 2024 Earnings Conference Call held on February 12, 2025, the company provided detailed guidance on its ongoing and upcoming clinical programs. The CEO, Jon Congleton, highlighted the anticipation of top-line data for the Advance-HTN trial, which enrolled 285 subjects, in March 2025, while the Launch-HTN trial, with 1083 subjects, is expected to provide results in the mid-first half of 2025. These pivotal trials aim to evaluate lorundrostat as an add-on therapy for uncontrolled or resistant hypertension. Additionally, the company is conducting exploratory Phase II trials, Explore-CKD and Explore-OSA, targeting hypertension in chronic kidney disease and obstructive sleep apnea, respectively, with results expected in the second quarter of 2025. Financially, the company ended 2024 with $198.2 million in cash equivalents and investments, projecting sufficient funding through Q1 2026. Research and development expenses for 2024 were $168.6 million, reflecting increased clinical and pre-clinical costs, while general and administrative expenses rose to $23.8 million.Strong Clinical Progress
The company has made significant advancements in its clinical pipeline, including the completion of enrollment for pivotal trials Advance-HTN and Launch-HTN, as well as the Phase II trials Explore-CKD and Explore-OSA.
Robust Financial Position
Mineralys ended the year with $198.2 million in cash, cash equivalents, and investments, sufficient to fund operations through Q1 2026.
Positive Market Potential for Lorundrostat
Lorundrostat has shown promising results in previous trials, with favorable safety and efficacy anticipated to address unmet needs in hypertension and related conditions.
---
MLYS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
MLYS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 12, 2025 | $9.66 | $10.63 | +10.04% |
| Nov 11, 2024 | $14.92 | $13.38 | -10.32% |
| Aug 13, 2024 | $11.83 | $9.13 | -22.82% |
| May 09, 2024 | $14.65 | $14.27 | -2.59% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Mineralys Therapeutics, Inc. (MLYS) report earnings?
Mineralys Therapeutics, Inc. (MLYS) is schdueled to report earning on May 19, 2025, TBA Not Confirmed.
What is Mineralys Therapeutics, Inc. (MLYS) earnings time?
Mineralys Therapeutics, Inc. (MLYS) earnings time is at May 19, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MLYS EPS forecast?
MLYS EPS forecast for the fiscal quarter 2025 (Q1) is -1.08.
---